A detailed history of Hudson Bay Capital Management LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 40,000 shares of NBIX stock, worth $5.42 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
40,000
Previous 45,000 11.11%
Holding current value
$5.42 Million
Previous $6.2 Million 25.67%
% of portfolio
0.02%
Previous 0.03%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$114.58 - $153.15 $572,900 - $765,750
-5,000 Reduced 11.11%
40,000 $4.61 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $1.96 Million - $2.15 Million
15,000 Added 50.0%
45,000 $6.2 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $3.59 Million - $3.95 Million
-27,500 Reduced 47.83%
30,000 $4.14 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $795,525 - $995,699
7,500 Added 15.0%
57,500 $7.58 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $2.59 Million - $3.22 Million
-27,500 Reduced 35.48%
50,000 $5.63 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $4.25 Million - $4.98 Million
47,500 Added 158.33%
77,500 $7.31 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $1.8 Million - $2.36 Million
19,160 Added 176.75%
30,000 $3.04 Million
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $10 Million - $12 Million
-94,160 Reduced 89.68%
10,840 $1.29 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $5.98 Million - $7.01 Million
-65,000 Reduced 38.24%
105,000 $11.2 Million
Q2 2022

Aug 12, 2022

BUY
$75.79 - $100.07 $1.14 Million - $1.5 Million
15,000 Added 9.68%
170,000 $16.6 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $1.45 Million - $1.9 Million
20,000 Added 14.81%
155,000 $14.5 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $4.39 Million - $5.85 Million
55,111 Added 68.98%
135,000 $11.5 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $852,234 - $979,307
9,889 Added 14.13%
79,889 $7.66 Million
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $447,150 - $511,350
5,000 Added 7.69%
70,000 $6.81 Million
Q1 2021

May 14, 2021

SELL
$87.57 - $119.4 $437,849 - $597,000
-5,000 Reduced 7.14%
65,000 $6.32 Million
Q4 2020

Feb 12, 2021

BUY
$86.91 - $108.33 $3.48 Million - $4.33 Million
40,000 Added 133.33%
70,000 $6.71 Million
Q3 2020

Nov 12, 2020

BUY
$96.16 - $135.15 $2.88 Million - $4.05 Million
30,000 New
30,000 $2.89 Million
Q2 2020

Aug 12, 2020

SELL
$85.09 - $130.36 $850,900 - $1.3 Million
-10,000 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$75.11 - $113.76 $751,100 - $1.14 Million
10,000 New
10,000 $866,000
Q3 2019

Nov 13, 2019

SELL
$83.82 - $101.5 $2.51 Million - $3.05 Million
-30,000 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $1.81 Million - $2.28 Million
25,000 Added 500.0%
30,000 $2.53 Million
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $346,550 - $457,650
5,000 New
5,000 $441,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.